Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

Launched by CLINIQUES UNIVERSITAIRES SAINT-LUC- UNIVERSITÉ CATHOLIQUE DE LOUVAIN · Dec 3, 2024

Keywords

ClinConnect Summary

The BELGICA trial is studying a new approach to treating glioblastoma, which is an aggressive type of brain tumor. The goal of the trial is to see if giving radiotherapy in a more focused way can reduce side effects and improve the quality of life for patients. Typically, radiotherapy targets not only the tumor but also a surrounding area called the Clinical Target Volume (CTV) to make sure any hidden cancer cells are treated. However, this can also damage healthy brain tissue, leading to unwanted side effects. By limiting the CTV, the trial hopes to minimize the amount of healthy brain exposed to radiation while still effectively treating the tumor.

To participate in the BELGICA trial, you need to be at least 18 years old, have been diagnosed with glioblastoma, and be able to give informed consent. You should also be in good enough health to participate, as determined by a medical team. If you join the trial, you can expect to receive focused radiotherapy and be monitored closely for any effects on your health and quality of life. The trial is not yet recruiting patients, but it aims to provide valuable information that could lead to better treatment options for glioblastoma in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants capable of giving informed consent
• • Age \>= 18 y.o.
• • WHO performance status 0-2
• • Newly diagnosed glioblastoma (Histologically proven glioblastoma per WHO 2021 classification based on biopsy or resection )
• • Indication of chemoradiotherapy confirmed by multidisciplinary tumour board
• Exclusion Criteria:
• • Participation in a competing trial
• • Known contraindication to undergo MRI scans